Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Somapacitan-induced reversible lipoatrophy in an adult woman with hypopituitarism.

Rakusa M, Janez A, Jensterle M

Pituitary9 Aug 2024Cited by 2 (Europe PMC)

PMID39120809 (opens in a new tab)PMCIDPMC11513695 (opens in a new tab)DOI10.1007/s11102-024-01440-w (opens in a new tab)PepBankPUB-39120809
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

BackgroundLipoatrophy is rare adverse event (AE) in daily recombinant human growth hormone (rhGH). Data on lipoatrophy in newly developed long-acting GH (LAGH) are scarce. We report the first case of lipoatrophy in adult patient treated with LAGH somapacitan.Case presentationA 38-year-old woman with congenital panhypopituitarism was transitioned from daily rhGH 0.4 mg QD to somapacitan dose 4 mg QW due to non-adherence to daily rhGH. Despite adequate education and regular changing of injection sites, the patient reported reduced subcutaneous tissue at all four injection sites, after the 4th application of somapacitan. Somapacitan was discontinued at patient preference and lipoatrophy completely reversed after 3 months.ConclusionsLipoatrophy caused by somapacitan was completely reversible. We speculate that high initial dose and volume of somapacitan caused delayed diffusion and a direct local lipolytic effect in our patient. Although, titration of somapacitan was initiated as previously reported in REAL2 study protocol, recent clinical guidelines advise more gradual increase of somapacitan dose also in women on oral estogens that are switched from daily rhGH. Importantly, our case and the two previously described cases in children in the REAL 3 study showed that lipoatrophy caused by somapacitan was transient and completely reversible, and that discontinuation of the drug is not always mandatory.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman with panhypopituitarism, subcutaneous tissue decreased at all four injection sites after the fourth somapacitan application.

    In plain wordsIn a woman with panhypopituitarism, tissue beneath the skin decreased at all four injection sites after the fourth somapacitan application.

    Peptide
    Somapacitan
    Outcome
    DecreaseInjection-site lipoatrophy
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    4 mg weeklyAs given in this study (human).

    Measurements

    Affected injection sites
    4 sites

    Source sentences

    Summary
    Despite adequate education and regular changing of injection sites, the patient reported reduced subcutaneous tissue at all four injection sites, after the 4th application of somapacitan.
    1 context sentence
    Summary · context
    A 38-year-old woman with congenital panhypopituitarism was transitioned from daily rhGH 0.4 mg QD to somapacitan dose 4 mg QW due to non-adherence to daily rhGH.
  2. 02HumanCase report or seriesSafety outcome

    In a woman with panhypopituitarism, lipoatrophy completely reversed three months after somapacitan discontinuation.

    In plain wordsIn a woman with panhypopituitarism, tissue loss completely reversed three months after somapacitan was stopped.

    Peptide
    Somapacitan
    Outcome
    DecreaseLipoatrophy reversal
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    4 mg weeklyAs given in this study (human).

    Measurements

    Time to reversal
    3 months
    after discontinuation

    Source sentences

    Summary
    Somapacitan was discontinued at patient preference and lipoatrophy completely reversed after 3 months.
    1 context sentence
    Summary · context
    A 38-year-old woman with congenital panhypopituitarism was transitioned from daily rhGH 0.4 mg QD to somapacitan dose 4 mg QW due to non-adherence to daily rhGH.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.